Question-and-Answer Session
Operator
Thank you sir. (Operator Instructions). And our first question comes from the line of Joe Pantginis of Merriman Curhan. Please proceed
Joe Pantginis - Merriman Curhan
Thanks for the update. Quick question to forward-looking, obviously we spend a lot of time talking about the upcoming Phase 3 data and we are all looking for a positive outcome hopefully may be you could just now fast forward a little bit you did mentioned a couple of the potential markets you might be looking to go in and start studies and any initial type of color you can give with regard to what these studies might look like either for an endoscopy study or a pancreatic cancer study?
Walter Herlihy
Well I think in the case of pancreatic cancer, we would be interested in seeing if we can reproduce the findings in literature that demonstrate an approximately 20 patients that the use of secretin enhances ones ability to define the edges not the size of a pancreatic tumor, and so we have protocols under development for that particular application, and we would hope to as soon as we get IRB approval initiate such a study in the first half of 2010.
Obviously if we get positive result there then we would expand to a larger more robust Phase 2 study. Second thing we are examining right now we have under IRB review at a single sight is the use of RG1068 to enhance the ability to visualize pancreatic abnormalities when using an ultrasonic evaluation which is an alternative to MRI and again that’s so it is about the same place assuming we get IRB approval this year we would start that in the first half of 2010 as well.
Joe Pantginis - Merriman Curhan
Great, well thanks a lot. And good luck with the Phase 3.
Operator
(Operator Instructions). And our next question comes from the line of Michael Panaro of MDP Associates.
Michael Panaro - MDP Associates
The wind side still indicates that you are investigation RG1068 for using, determining pancreatic function. Can you explain whether you have stopped doing that and how that would relate to the ChiRhoClin the secretin which products which are apparently already have FDA approval that is for use with..
Walter Herlihy
We had done some studies with collaborators using RG1068 to look at the ability to detect changes in pancreatic fluid production in patients with disease and while we have some interesting data there, we think that the results there are not as robust as they are in some other areas, so we’ve chosen to focus on the areas I just mentioned, the enhancement of MRI replacement endoscopy, pancreatic cancer and ultrasound as the first four statements to attack. We may come back to that later, but at the moment we think there are larger and more discreet opportunities in other areas.
- To read the full transcript on Seeking Alpha, click here »
